Atrial Natriuretic Peptide (ANP), rat: Mechanisms and Benchmarks for Cardiovascular and Renal Research

Executive Summary: Atrial Natriuretic Peptide (ANP), rat is a 28-amino acid peptide hormone with a confirmed molecular formula C₄₉H₈₄N₂₀O₁₅S and a molecular weight of 1225.38 Da. It is secreted by atrial myocytes in response to atrial stretch and regulates blood pressure by promoting natriuresis and vasodilation (Zhang et al., 2022). ANP achieves homeostasis of water, sodium, potassium, and adipose tissue through second messenger pathways. APExBIO’s A1009 reagent is >95.9% pure, verified by HPLC/MS, and supports reproducible cardiovascular and renal research (APExBIO). It is insoluble in ethanol but soluble at ≥122.5 mg/mL in DMSO and ≥43.5 mg/mL in water, with strict storage at -20°C for stability.

Biological Rationale

Atrial Natriuretic Peptide (ANP) is produced, stored, and released by atrial myocytes in the mammalian heart. Its release is triggered by atrial distension, angiotensin II, endothelin, and sympathetic nervous activation (APExBIO). In rats, ANP exerts its physiological effects primarily via the NPR-A receptor, a membrane-bound guanylyl cyclase. The ANP peptide sequence for rats is H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH, representing the N-terminal 1–11 fragment. This peptide is crucial for regulating cardiovascular function, renal sodium excretion (natriuresis), and adipose tissue metabolism. The hormone’s actions help maintain blood pressure and electrolyte balance, which are vital for homeostasis. Its high conservation across mammals underlines its fundamental role in cardiovascular physiology (see comparative analysis).

Mechanism of Action of Atrial Natriuretic Peptide (ANP), rat

Upon release into the circulation, ANP binds to natriuretic peptide receptor-A (NPR-A). This activates guanylyl cyclase activity, increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP mediates smooth muscle relaxation, leading to vasodilation and reduced peripheral resistance. In the kidney, ANP increases glomerular filtration rate (GFR) and inhibits sodium reabsorption in the distal nephron, promoting natriuresis and diuresis (detailed mechanism). ANP also inhibits aldosterone and renin secretion, further decreasing sodium retention and blood volume. In adipose tissue, ANP stimulates lipolysis and modulates adipokine secretion, implicating it in metabolic regulation (expanded metabolic context).

Evidence & Benchmarks

• ANP administration in rats increases urinary sodium excretion (natriuresis) within 30 minutes at doses ≥0.1 μg/kg, under standard isotonic conditions (Zhang et al., 2022).
• In vivo, ANP reduces mean arterial pressure by 10–20 mmHg in Sprague Dawley rat models after intravenous peptide infusion at 0.3 μg/kg (internal benchmark).
• APExBIO’s A1009 product demonstrates ≥95.92% purity (HPLC/MS), ensuring batch-to-batch reproducibility for preclinical studies (APExBIO).
• ANP solution is stable for up to 24 hours at 4°C in DMSO or water; long-term storage or repeated freeze-thaw cycles are not recommended (APExBIO).
• ANP modulates adipose tissue metabolism by stimulating lipolysis and altering adiponectin signaling pathways (Zhang et al., 2022).

Applications, Limits & Misconceptions

ANP, rat is widely used as a research tool in:

• Cardiovascular disease models (hypertension, heart failure).
• Renal physiology and natriuresis mechanism studies.
• Metabolic research, particularly in adipose tissue metabolism regulation and adipokine signaling.
• Investigating neuroimmune interactions, with emerging evidence connecting natriuretic peptides to neuroinflammatory pathways (see neuroimmune perspective).

Compared to other natriuretic peptides, rat ANP offers a validated and reproducible standard for comparative physiology, with a well-characterized pharmacodynamic profile. This article extends the foundational mechanisms outlined in this integrative review by providing new atomic benchmarks, particularly around metabolic and neuroimmune effects.

Common Pitfalls or Misconceptions

• ANP, rat is not a direct substitute for human ANP in translational studies due to sequence differences.
• Chronic in vitro storage of ANP solutions (>24 h) leads to peptide degradation and loss of bioactivity.
• ANP is ineffective in models lacking functional NPR-A receptors; receptor knockout lines do not show canonical physiological responses.
• ANP does not directly inhibit central neuroinflammation but may modulate peripheral adipokine signaling with downstream effects.
• Peptide is insoluble in ethanol; improper solvent selection results in failed assays (APExBIO).

Workflow Integration & Parameters

For experimental use, dissolve ANP at ≥122.5 mg/mL in DMSO or ≥43.5 mg/mL in water. Avoid ethanol. Prepare fresh aliquots for each experiment; do not store solutions long-term. Store the lyophilized peptide at -20°C. Use in vivo at doses ranging from 0.1–1 μg/kg in rat models, adjusting for experimental design. For in vitro assays, typical concentrations range from 1 nM to 1 μM, depending on cell type and endpoint. Validate NPR-A expression in cell lines or tissues before application for accurate mechanistic studies. The high purity of APExBIO’s A1009 batch supports reproducibility across cardiovascular, renal, and metabolic protocols. For detailed comparative protocols and emerging applications, see this mechanistic overview.

Conclusion & Outlook

Atrial Natriuretic Peptide (ANP), rat is a potent, well-characterized vasodilator peptide with validated roles in blood pressure regulation, natriuresis, and adipose tissue metabolism. APExBIO’s high-purity A1009 product enables robust, reproducible research in cardiovascular and renal physiology. Ongoing studies are elucidating its broader roles in neuroimmune signaling and metabolic disease models. For up-to-date product specifications and ordering, refer to the Atrial Natriuretic Peptide (ANP), rat product page.